Renasant Bio is a technology company.
Renasant Bio has raised $55.0M across 1 funding round.
Renasant Bio has raised $55.0M in total across 1 funding round.
Renasant Bio is a biopharmaceutical company developing oral small molecule therapies—correctors and potentiators—to target the underlying biology of autosomal dominant polycystic kidney disease (ADPKD), the most common genetic cause of end-stage renal failure affecting around 12 million people worldwide, including 300,000 in the US.[1][2][4][5] It serves ADPKD patients by restoring function to mutated polycystin proteins (PC1 and PC2), aiming to halt cyst formation and kidney enlargement, unlike current treatments that only manage symptoms.[2][3][4] The company launched in July 2025 with $54.5 million in seed funding from 5AM Ventures, Atlas Venture, OrbiMed, and Qiming Venture Partners, supporting a preclinical pipeline including a lead corrector candidate for broad mutations and a complementary potentiator.[1][2][4]
Early momentum includes incubation by 5AM Ventures and a focused "all-in" strategy on ADPKD, drawing from cystic fibrosis successes like Vertex's Trikafta.[3][4] Leadership features CEO Emily Conley, PhD, and Chief Scientific Officer Gus Gustafson, backed by a board with experts like Natalie Holles and a Scientific Advisory Board including Nira Dahl.[3][4][6]
Renasant Bio emerged from 5AM Ventures' incubation around a "bold idea" to apply cystic fibrosis-style corrector-potentiator therapies to ADPKD, a complex channelopathy causing massive kidney cysts.[2][3][4] Founded in 2025, it launched publicly on July 14, 2025, with $54.5 million seed funding, marking strong early validation from top VCs.[1][2] CEO Emily Conley leads with a vision to fix cellular defects at the root, emphasizing the disease's heterogeneity and unmet need beyond drugs like Tolvaptan.[3][5]
The team humanizes the mission: Conley highlights patients' struggles, like wearing "I'm not pregnant, I have ADPKD" shirts due to enlarged kidneys weighing up to 30 pounds each.[5] Key hires like Gustafson (ex-Johnson & Johnson, Merck) and advisors like Dahl (veteran of major ADPKD trials) bring deep polycystic disease expertise, while the board—majority women—includes Natalie Holles (ex-Third Harmonic Bio CEO).[3][4][6] This assembly reflects pivotal focus on precision assays for protein trafficking and electrophysiology.[2]
Renasant rides the kidney disease biotech wave, where investors eye genetic renal disorders amid rising end-stage failure cases, competing with Novartis, Regulus, and Vertex but differentiating via root-cause correction.[4][5] Timing aligns with CF therapeutic breakthroughs proving channelopathy modulation works, now adapting to ADPKD's 12 million global patients—a massive, underserved market with no true disease modifiers.[2][4][5] Favorable forces include advancing genetic testing (e.g., Metera) for patient stratification and preclinical tools accelerating pipelines.[3]
By focusing exclusively on ADPKD, Renasant influences the ecosystem through expertise-sharing via its SAB and potential to redefine renal medicine, much like Vertex transformed CF—potentially enabling combo therapies and inspiring related channelopathies.[3][4]
Renasant Bio's preclinical corrector (standalone potential) and potentiator combo could reach clinical trials in the next few years, targeting first disease-modifying ADPKD approval amid growing VC interest in nephrology.[4] Trends like AI-driven discovery, genetic diagnostics, and combo regimens will shape its path, with competition from Vertex accelerating validation.[4][5] Influence may evolve from stealth pioneer to ecosystem leader, partnering on trials or expanding to polycystic liver disease if successful—ultimately offering hope to transform "ballooning" kidneys from fate to fixable.[2][5] This seed-funded launch positions Renasant to lead the next era of precision renal therapies.
Renasant Bio has raised $55.0M in total across 1 funding round.
Renasant Bio's investors include 5AM Ventures, Atlas Venture.
Renasant Bio has raised $55.0M across 1 funding round. Most recently, it raised $55.0M Seed in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $55.0M Seed | 5AM Ventures, Atlas Venture |